Do the benefits of being a smoker hint at the existence of PD-1/PD-L1 sensitizers for patients on single-agent immunotherapy?

Multiple studies demonstrate significantly better therapeutics outcomes in smokers as compared with never smokers when single-agent immunotherapy is applied. Non-smoker patients usually need a combination of chemoimmunotherapy to achieve comparable or slightly better therapeutic results. This effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaleskis, Gintaras, Pasukoniene, Vita, Characiejus, Dainius, Urbonas, Vincas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Hypothesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378371/
https://www.ncbi.nlm.nih.gov/pubmed/34413168
http://dx.doi.org/10.1136/jitc-2021-003191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378371/
https://www.ncbi.nlm.nih.gov/pubmed/34413168
http://dx.doi.org/10.1136/jitc-2021-003191

Ejemplares similares